1. Department of Neurology, the Second Affiliated Hospital of Gannan Medical University, Jiangxi Province, Ganzhou 341000, China;
2. Graduate School of Gannan Medical University, Jiangxi Province, Ganzhou 341000, China;
3. Department of Cardiovascular Medicine, the Second Affiliated Hospital of Gannan Medical University, Jiangxi Province,Ganzhou 341000, China
Abstract：Objective To investigate the clinical efficacy of Ginkgo Armillaria Oral Solution combined with Flupentixol and Melitracen in the treatment of post ischemic stroke depression. Methods A total of 100 patients with mild to moderate post ischemic stroke depression admitted to the Department of Neurology in the Second Affiliated Hospital of Gannan Medical University from January 2019 to February 2020 were selected as subjects. They were divided into two groups with 50 cases in each group by random number parity method. The patients in the two groups were given routine treatment and necessary rehabilitation treatment. The control group was treated with Flupentixol and Melitracen on the basis of routine treatment, and the experimental group was treated with Flupentixol and Melitracen and Ginkgo Armillaria Oral Solution on the basis of routine treatment. The patients in the two groups were treated continuously for 4 weeks. Hamilton depression scale (HAMD) score and Barthel index (BI) were compared between the two groups before and after treatment.The clinical efficacy of the two groups was compared.The incidence of adverse reactions was compared between the two groups. Results The HAMD scores of the two groups after treatment were lower than those before treatment, BI scores of the two groups after treatment were higher than those before treatment, the differences were statistically significant (P<0.05). After treatment, HAMD score of experimental group was lower than that of control group, BI score was higher than that of control group, the differences were statistically significant (P<0.05). The total effective rate of experimental group (90.00%) was higher than that of control group (74.00%), and the difference was statistically significant (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). Conclusion The effect of Ginkgo Armillaria Oral Solution combined with Flupentixol and Melitracen in the treatment of post ischemic stroke depression is better than that of Flupentixol and Melitracen alone, and it can improve the patients′ ability of daily living and depression symptoms at 4 weeks.
Wang W，Jiang B，Sun H，et al.NESS-China Investigators.Prevalence，Incidence，and Mortality of Stroke in China：Results from a Nationwide Population-Based Survey of 480 687 Adults[J].Circulation，2017，135（8）：759-771.
[3]
Feigin VL，Norrving B，Mensah GA.Global Burden of Stroke[J].Circ Res，2017，120（3）：439-448.
[4]
Villa RF，Ferrari F，Moretti A.Post-stroke depression：Mechanisms and pharmacological treatment[J].Pharmacol Ther，2018，184：131-144.
Li Y，Zhang X，Chen L，Yang B，et al.Cerebellar fastigial nucleus is involved in post-stroke depression through direct cerebellar-hypothalamic GABAergic and glutamatergic projections[J].Exp Ther Med，2019，18（4）：2885-2892.
[15]
Liang J，Yue Y，Jiang H，et al.Genetic variations in the p11/tPA/BDNF pathway are associated with post stroke depression[J].J Affect Disord，2018，226：313-325.
京公网安备 11010502046607号